Skip to main content
BioVaxys Technology Corp. logo

BioVaxys Technology Corp. — Investor Relations & Filings

Ticker · BIOV ISIN · CA09076M2004 LEI · 894500UD22QWRLZYJ229 CSE Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2021-03-24 Regulatory Filings
Country CA Canada
Listing CSE BIOV

About BioVaxys Technology Corp.

https://biovaxys.com/

BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company specializing in the development and out-licensing of novel immunotherapy assets. The core technology is the proprietary DPX™ platform, a unique lipid-in-oil formulation designed for sustained, targeted immune responses. DPX forces active uptake into immune cells and lymph nodes, avoiding systemic side effects common to conventional delivery methods. The platform is versatile, supporting peptides, proteins, mRNA, and small molecules, and is being applied across oncology, infectious disease, allergy, and autoimmune disorders. The lead clinical asset, Maveropepimut-S (MVP-S), has demonstrated promising Phase 2B results in recurrent ovarian cancer and relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL). The company is also integrating Artificial Intelligence to enhance immunotherapeutic discovery.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2021-03-24 English
News release - English.pdf
Regulatory Filings
2021-03-18 English
News release - English.pdf
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of Tarik Lebbadi as Chief Operating Officer of Mind Cure Health Inc. It focuses on management changes and biographical details of the new COO. There is no financial data, no discussion of financial results, no regulatory filings, or other report types. The content clearly fits the category of announcing changes in senior management. Therefore, the document is best classified as Board/Management Information (MANG). The document length is sufficient and the content is detailed about the management change, not a brief mention or a report publication announcement.
2021-03-15 English
52-109F1-AIF - Certification of filings with voluntarily filed AIF - CFO(E).pdf
Regulatory Filings
2021-03-10 English
52-109F1-AIF - Certification of filings with voluntarily filed AIF - CEO(E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification form titled 'FORM 52-109F1 – AIF CERTIFICATION OF ANNUAL FILINGS IN CONNECTION WITH VOLUNTARILY FILED AIF' filed by the CEO of BioVaxys Technology Corp. It certifies the review and fair presentation of the annual filings including the AIF, annual financial statements, and annual MD&A for the financial year ended October 31, 2020. The document is primarily an officer certification letter confirming the accuracy and completeness of the annual filings. It does not contain actual financial data or the full annual report itself but serves as a certification related to those filings. According to the CERTIFICATION RULE, such officer certifications should be classified as Regulatory Filings (RNS) rather than the report they reference. The document length is 3227 characters, which is relatively short and consistent with a certification letter rather than a full report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-03-10 English
Annual information form - English.pdf
Regulatory Filings Classification · 95% confidence The document is titled 'Annual Information Form' for the financial year ended October 31, 2020, dated March 10, 2021. It contains detailed sections typical of an Annual Information Form such as corporate structure, business description, risk factors, dividends, capital structure, market for securities, directors and officers, legal proceedings, audit committee information, and additional information. The document is comprehensive and exceeds 15,000 characters, indicating it is a full report rather than a brief announcement. An Annual Information Form (AIF) is a regulatory filing commonly used in Canada that supplements the Annual Report (10-K equivalent) by providing detailed corporate and business information. Given the detailed nature and the title, this document fits best under the category of Regulatory Filings (RNS) because the AIF is a specific regulatory filing distinct from the Annual Report (10-K) and other categories. It is not an Annual Report (10-K) itself, nor an Audit Report, nor a Management Report. The AIF is a regulatory disclosure document required by Canadian securities regulators, thus best classified as Regulatory Filings (RNS).
2021-03-10 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.